57 related articles for article (PubMed ID: 21475875)
21. Implication for the CD94/NKG2A-Qa-1 system in the generation and function of ocular-induced splenic CD8+ regulatory T cells.
Chattopadhyay S; O'Rourke J; Cone RE
Int Immunol; 2008 Apr; 20(4):509-16. PubMed ID: 18359787
[TBL] [Abstract][Full Text] [Related]
22. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors.
Korbelik M; Dougherty GJ
Cancer Res; 1999 Apr; 59(8):1941-6. PubMed ID: 10213504
[TBL] [Abstract][Full Text] [Related]
23. Accumulation in tumor tissue of adoptively transferred T cells: A comparison between intravenous and intraperitoneal injection.
Petersen CC; Petersen MS; Agger R; Hokland ME
J Immunother; 2006; 29(3):241-9. PubMed ID: 16699367
[TBL] [Abstract][Full Text] [Related]
24. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.
Roychowdhury S; May KF; Tzou KS; Lin T; Bhatt D; Freud AG; Guimond M; Ferketich AK; Liu Y; Caligiuri MA
Cancer Res; 2004 Nov; 64(21):8062-7. PubMed ID: 15520217
[TBL] [Abstract][Full Text] [Related]
25. Bryostatin/ionomycin-activated T cells mediate regression of established tumors.
Chin CS; Graham LJ; Hamad GG; George KR; Bear HD
J Surg Res; 2001 Jun; 98(2):108-15. PubMed ID: 11397126
[TBL] [Abstract][Full Text] [Related]
26. Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab.
Ramakrishna V; Sundarapandiyan K; Zhao B; Bylesjo M; Marsh HC; Keler T
J Immunother Cancer; 2015; 3():37. PubMed ID: 26500773
[TBL] [Abstract][Full Text] [Related]
27. PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8
Bowers JS; Majchrzak K; Nelson MH; Aksoy BA; Wyatt MM; Smith AS; Bailey SR; Neal LR; Hammerbacher JE; Paulos CM
Front Immunol; 2017; 8():1221. PubMed ID: 29033940
[TBL] [Abstract][Full Text] [Related]
28. BAT6026, a novel anti-OX40 antibody with enhanced antibody dependent cellular cytotoxicity effect for cancer immunotherapy.
Liang S; Zheng D; Liu X; Mei X; Zhou C; Xiao C; Qin C; Yue H; Lin J; Liu C; Li S; Yu JC
Front Oncol; 2023; 13():1211759. PubMed ID: 37576888
[TBL] [Abstract][Full Text] [Related]
29. Effective adoptive T-cell therapy for cancer in the absence of host lymphodepletion.
Gilham DE
Immunotherapy; 2011 Feb; 3(2):177-9. PubMed ID: 21322758
[TBL] [Abstract][Full Text] [Related]
30. Sunitinib represses regulatory T cells to overcome immunotolerance in a murine model of hepatocellular cancer.
Liu D; Li G; Avella DM; Kimchi ET; Kaifi JT; Rubinstein MP; Camp ER; Rockey DC; Schell TD; Staveley-O'Carroll KF
Oncoimmunology; 2017; 7(1):e1372079. PubMed ID: 29296523
[TBL] [Abstract][Full Text] [Related]
31. Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors.
Albershardt TC; Leleux J; Parsons AJ; Krull JE; Berglund P; Ter Meulen J
NPJ Vaccines; 2020; 5(1):50. PubMed ID: 32579133
[TBL] [Abstract][Full Text] [Related]
32. The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells.
Kuczma MP; Ding ZC; Li T; Habtetsion T; Chen T; Hao Z; Bryan L; Singh N; Kochenderfer JN; Zhou G
Oncotarget; 2017 Dec; 8(67):111931-111942. PubMed ID: 29340102
[TBL] [Abstract][Full Text] [Related]
33. Engineering effective T-cell based antitumor immunity.
Gruber T; Hinterleitner R; Pfeifhofer-Obermair C; Wolf D; Baier G
Oncoimmunology; 2013 Feb; 2(2):e22893. PubMed ID: 23525844
[TBL] [Abstract][Full Text] [Related]
34. Role of Metabolism in Adoptive T Cell Therapy: Strategies and Challenges.
Tan GH; Wong CC
Antioxid Redox Signal; 2022 Dec; 37(16-18):1303-1324. PubMed ID: 35538791
[No Abstract] [Full Text] [Related]
35. Immune correlates of melanoma survival in adoptive cell therapy.
Lee AF; Sieling PA; Lee DJ
Oncoimmunology; 2013 Feb; 2(2):e22889. PubMed ID: 23525606
[TBL] [Abstract][Full Text] [Related]
36. Toward understanding the genetics of regulatory T cells in ovarian cancer.
Derycke MS; Charbonneau B; Preston CC; Kalli KR; Knutson KL; Rider DN; Goode EL
Oncoimmunology; 2013 Jun; 2(6):e24535. PubMed ID: 23894717
[TBL] [Abstract][Full Text] [Related]
37. It's the peptide-MHC affinity, stupid.
Kammertoens T; Blankenstein T
Cancer Cell; 2013 Apr; 23(4):429-31. PubMed ID: 23597560
[TBL] [Abstract][Full Text] [Related]
38. Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle.
Lickefett B; Chu L; Ortiz-Maldonado V; Warmuth L; Barba P; Doglio M; Henderson D; Hudecek M; Kremer A; Markman J; Nauerth M; Negre H; Sanges C; Staber PB; Tanzi R; Delgado J; Busch DH; Kuball J; Luu M; Jäger U
Front Immunol; 2023; 14():1303935. PubMed ID: 38187393
[TBL] [Abstract][Full Text] [Related]
39. Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models.
Hoffmann PR; Hoffmann FW; Premeaux TA; Fujita T; Soprana E; Panigada M; Chew GM; Richard G; Hindocha P; Menor M; Khadka VS; Deng Y; Moise L; Ndhlovu LC; Siccardi A; Weinberg AD; De Groot AS; Bertino P
Front Oncol; 2019; 9():720. PubMed ID: 31428586
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic modification and preliminary investigation of the mechanism of the immune evasion of HL-60 cells.
Liu JH; Bian YM; Xie Y; Lu DP
Mol Med Rep; 2015 Jul; 12(1):1059-65. PubMed ID: 25815463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
